Investors & Media

Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology’s Kidney Week 2022

–     IONIS-FB-L Rx achieved a 44% mean reduction in proteinuria in patients treated for 6 months –     Roche to advance IONIS-FB-L Rx into Phase 3 development in H1 2023 CARLSBAD, Calif. , Nov. 7, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from

Read more
You are now leaving to visit